ClinicalTrials.gg
CompletedNCT06903715Updated Jun 13, 2025

A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)

A Phase 1 interventional study of Belzutifan and Phenytoin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Researchers designed belzutifan, the study medicine, to treat certain kinds of cancer.

The goal of this study is to learn what happens to belzutifan in a healthy person's body over time when taken, by mouth, as a tablet. Researchers will learn what happens when belzutifan is taken alone and when it is taken after several days of treatment with phenytoin.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Healthy, adult, male (vasectomized or surgically sterilized) or female (of non-)
  • Has a (BMI) ≥ 18.0 and ≤ 32.0 kg/m2

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study
  • History or presence of: Seizure (excluding simple febrile seizure), epilepsy, severe head injury, multiple sclerosis, or other known neurological conditions which the PI considers to be ; reaction to anticonvulsant therapy (including phenytoin, primidone, and phenobarbital); Depression, unusual changes in mood or behavior or suicidal thoughts and behavior; Hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Belzutifan + Phenytoin

    Participants receive belzutifan during study Period 1, followed by a washout period, then they receive belzutifan and phenytoin during study Period 2.

    Drug: Belzutifan · Drug: Phenytoin

Interventions

  • Oral administration

    Also known as: MK-6482, PT2977, Welireg™

  • Oral administration

    Also known as: Phenytoin sodium

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Belzutifan

    Blood samples will be collected to determine the AUC0-inf of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 36 days

  2. Number of Participants Who Discontinue Study Drug Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 22 days

  3. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of Belzutifan in Plasma

    Blood samples will be collected to determine the AUC0-last of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  4. Area Under the Concentration-Time Curve from Time 0 to 24 Hours (AUC0-24) of Belzutifan in Plasma

    Blood samples will be collected to determine the AUC0-24 of belzutifan.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  5. Maximum Plasma Concentration (Cmax) of Belzutifan in Plasma

    Blood samples will be collected to determine the Cmax of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  6. Plasma Concentration 24 Hours Postdose (C24) of Belzutifan in Plasma

    Blood samples will be collected to determine the C24 of belzutifan.

    Time frame: 24 hours postdose

  7. Time to Maximum Plasma Concentration (Tmax) of Belzutifan in Plasma

    Blood samples will be collected to determine the Tmax of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  8. Apparent Terminal Half-life (t1/2) of Belzutifan in Plasma

    Blood samples will be collected to determine the t1/2 of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  9. Apparent Clearance (CL/F) of Belzutifan in Plasma

    Blood samples will be collected to determine the CL/F of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  10. Apparent Volume of Distribution during terminal phase (Vz/F) of Belzutifan in Plasma

    Blood samples will be collected to determine the Vz/F of belzutifan.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

07

Study locations

1 site
  • Celerion, Inc. ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartActual
Mar 28, 2025
Primary completionActual
May 8, 2025
CompletionActual
May 27, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06903715
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Mar 28, 2025
Primary completion
May 8, 2025
Completion
May 27, 2025
Last update
Jun 13, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belzutifan · Phenytoin

Start the discussion